The Status of Advisory Committees to the Federal Statistical Agencies

1990 ◽  
Vol 44 (2) ◽  
pp. 154
Author(s):  
Marie D. Eldridge
2015 ◽  
Vol 8 (5) ◽  
pp. 1-9 ◽  
Author(s):  
Jennifer Hunter Childs ◽  
Ryan King ◽  
Aleia Clark Fobia

Author(s):  
Gerald W. Gates

U.S. federal statistical agencies continually face challenges in obtaining and using administrative records and in providing useful analytic products to support policy analysis and program planning. At each of three decision points—obtaining the administrative data, integrating the data into statistical programs, and releasing useful data products—concerns over privacy and confidentiality determine to a great extent how effectively these data are used. Although there is a long history of relevant research on privacy attitudes and methodologies to protect conconfidentiality in published data, agency decisions to share or publish data are not necessarily informed by known risks. Additional research is proposed to help identify and manage these risks. The paper also proposes government actions to ensure that U.S. federal statistical agencies are meeting the nation's data needs through the appropriate application of survey and administrative data.


Author(s):  
Margo J. Anderson ◽  
William Seltzer

The roots of the modern concept of statistical confidentiality in the US federal statistical system can be traced directly back to the late nineteenth century efforts of statisticians to ensure full and accurate responses by businesses to statistical inquiries. Officials argued that such confidentiality guarantees were needed to ensure that the providers of enterprise and establishment data could be confident that the statistical agencies could not be forced to share their responses with others, such as regulatory or tax authorities, congressional investigators, prying journalists, and competitors, who might use this information to the detriment of the data provider. Nevertheless, over the years, the principle of statistical confidentiality with respect to information provided by businesses in statistical inquiries has been repeatedly challenged by other executive branch departments, independent regulatory agencies, the courts, Congress, and members of the public, with quite varied results. The paper uses the published record and archival research to examine the history of challenges to statistical confidentiality, and the responses of the statistical agencies, the federal statistical system as a whole, including the office of the chief statistician in OMB (and its predecessors), executive department and independent non-statistical agencies, the courts, and Congress as well as representatives of the business community. Long-term trends and the implications for maintaining and strengthening the confidentiality protections for establishment- and enterprise-level business data provided to federal agencies for statistical purposes are discussed.


HortScience ◽  
1992 ◽  
Vol 27 (6) ◽  
pp. 647a-647
Author(s):  
Mark A. Bohning ◽  
Allan K. Stoner

The United States' National Plant Germplasm System (NPGS) is responsible for the acquisition, preservation, evaluation and distribution of plant genetic resources in the form of seed and clonal germplasm. In order to operate more effectively, the NPGS established a network of 40 Crop Advisory Committees (CACs) to provide analysis, data, and advice about germplasm within a crop or group of related crops of current or future economic importance. CACs are composed of Federal, State and industry scientists representing a variety of agricultural disciplines and geographic areas of importance to the crop. The committees are involved in a variety of activities including: 1) Developing crop descriptors for the collection of standardized characteristic and evaluation data, 2) Determining priorities for germplasm acquisition, evaluation and enhancement, 3) Advising curators on maintenance techniques, and 4) Developing special reports on the status of genetic resources for their crop(s). Twenty-four of the CACs are concerned with horticultural crops.


Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 17-17
Author(s):  
Jia Li ◽  
Yue Wei ◽  
Minjung Lee ◽  
Hui Yang ◽  
Caleb Class ◽  
...  

Aberrant DNA hydroxymethylcytosine (5hmC) levels have been reported in patients with myelodysplastic syndromes (MDS). The dysregulation of 5hmC is not only observed in patients with TET2 mutations, but also those bearing other genetic defects, suggesting that 5hmC might act as a valuable epigenetic mark to reflect the status of MDS. We report herein a highly-sensitive 5hmC analysis method using low input DNA (10 ng), which was used to obtain a comprehensive atlas of the DNA hydroxymethylome in MDS patients. Our systematic bioinformatic analysis unveiled that 5hmC signatures could be used to separate patients with good and poor clinical outcomes. At the molecular level, we observed dynamic changes of 5hmC within several key transcription factor binding motifs that are essential for hematopoiesis and myeloid lineage specification, which might result in impaired transcriptional outputs during leukemogenesis. Interestingly, we also observed massive changes in 5hmC and transcriptomes in patient showing response to hypomethylating agent (HMA) treatment, suggesting the prognostic value of 5hmC in evaluating epigenetic therapy. Overall, our highly-sensitive 5hmC analysis method provides a useful means to potentially facilitate the clinical evaluation of MDS patients. Disclosures Garcia-Manero: AbbVie: Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Onconova: Research Funding; Amphivena Therapeutics: Research Funding; Astex Pharmaceuticals: Consultancy, Honoraria, Research Funding; Merck: Research Funding; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Research Funding; Jazz Pharmaceuticals: Consultancy; Acceleron Pharmaceuticals: Consultancy, Honoraria; H3 Biomedicine: Research Funding; Helsinn Therapeutics: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding.


Sign in / Sign up

Export Citation Format

Share Document